Cherneva R1, Dimova I2,*
*Corresponding Author: Dr. Ivanka Dimova, Department of Medical Genetics, Medical University, 2 Zdrave str., Floor 13, 1431 Sofia, Bulgaria; Tel./Fax: +359-2-952-03-57; E-mail:
page: 9


1. Smith AL, Hung J, Walker L. Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Br J Cancer 1996; 73(2): 203-209.

      2. Romeo NS, Sokolova IA, Morrison LE, Zeng Chan, Baron AE, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M. Chromosomal abnormalities in non-small cell lung cancer detected by FISH. J Mol Diagn 2003; 5(2): 103-112.

      3. Taguchi T, Zhou J, Feder M, Litwin S, Klein-Szanto A, Testa J. Detection of aneuploidy in interphase nuclei from non small cell lung carcinoma by FISH using chro­mosome specific repetitive DNA probes. Cancer Genet Cytogenet 1996; 89(2): 120-125.

      4. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP. Chromo­some 19 translocation, overexpression of Notch3 and hu­man lung cancer. J Nat Cancer Inst 2000; 92(16): 1355-1357.

      5. Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 2003; 22(13): 1988-1997.

      6. Balsara BR, Sonoda G, du Manior S, Siegfried JM, Gabrielson E, Testa JR. Comparative genomic hybridiza­tion analysis detects frequent, often high level of over representation of DNA sequence at 3q, 5p, 7p, 8q in NSCLC. Cancer Res 1997; 57(11): 2116-2120.

      7.Bjo rkqvist AM, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto A, Mattson K,Vainio H, Knuutila S. DNA gain in 3q occur frequently in squamous cell carcinoma of the lung but not in adenocarcinoma. Genes Chromosomes Cancer 1998; 22(1): 79-82.

      8. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen JW. Genomic copy number analysis of non-small cell lung cancer using array compar­ative genomic hybridization: implications of the phospha­tidylinositol 3-kinase pathway. Cancer Res 2002; 62(13): 3636-3640.

      9. Massion PP, Taflan PM, Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 ampli­fication and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63(21): 7113-7121.

      10. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert A, Noel S, Lafitte J, Sculier J. The role of RAS oncogene in survival of patients with lung cancer a systemic review of the literature with meta-analysis. Br J Cancer 2005; 92(1): 131-139.

      11. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung cancer. Semin Oncol 2001; 28 (2, Suppl 4): 3-13.

      12. Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, Kanai Y,Asamura H,Tsuchiya R, Hirohashi S. Mutation of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchoalveolar carcinoma of the lung. Lung Cancer 2005; 50(1): 1-8.

      13. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P.Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and non-smok­ing women. Cancer Epidemiol Biomarkers Prev 1999; 8(4, Pt 1): 297-302.

      14. Marchetti A, Martella C, Feliconi L, Barrassi F, Salvatore S, Chella A, Camplese PP, Iaruss T, Mucilli F, Mezzettia A, Cuccurullo A, Sacco R, Buttitta F. EGFR mutations in non-small cell lung carcinomas: analysis of a large series of cases and development of a rapid and sensi­tive method for diagnostic screening with potential impli­cations on pharmacologic treatment. J Clin Oncol 2005; 23(4): 857-865.

      15. Wong A, Ruppert J, Eggleston J. Gene amplifica­tion of C-myc and N-myc in small cell carcinoma of the lung. Lung Cancer 1987; 3(1): 21.

      16. Johnson A, Battey N, Linnoila I. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the C-myc proto-oncogene. Lung Cancer 1987; 3(1): 22-23.

      17. Plummer H III, Catlett J, Leftwich J. c-Myc expres­sion correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Lung Can­cer 1994; 11(5-6): 427.

      18.Yazawa T, Okudela K. c-Myc overexpression caus­es deficient class II transactivator expression in small cell lung cancer. Lung Cancer 2000; 29(1, Suppl 4): 189.

      19. Nau MM, Brooks BJ Jr, Carney, DN. Human small-cell lung cancers show amplification and expression of the n-myc gene. Proc Natl Acad Sci USA 1986; 83(4): 1092-1096.

      20. Scagiotti G, Selvaggi G, Novello S, Hirsch F. The biology of epidermal growth factor receptor: Clin Cancer Res 2004; 10(12): 4227-4232.

      21. Franklin WA, Veve R, Hirsch FR. Epidermal growth factor receptor family in lung cancer and premalig­nancy . Semin Oncol 2002; 29(1, Suppl 4): 3-14.

      22. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Hoshioka M, Suga M, Matsumoto M, Wong AJ. Expres­sion of constitutively activated EGFRvIII in non-small cell lung cancer .Cancer Sci 2003; 94(1): 50-56.

      23. Shigematsu H, Lin L ,Takahashi T, Nomura M, Suzuk M, Wistuba I, Fong K, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth J, Herz J, Minna J, Gazdar A. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97(5): 339-346.

      24. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21(20): 3798-3807.

      25. Holbro T, Civenni G, Hynes N. The ErbB recep­tors and their role in cancer progression. Exp Cell Res 2003; 284(1): 99-110.

      26. Hirsch FR, Franklin WA, Veve R. HER2/neu ex­pression in malignant lung tumors. Semin Oncol 2002; 29(Suppl 4): 51-58.

      27. Meert AP, Martin B, Paesmans M. The role of HER2/neu expression on the survival of patients with lung cancer a systematic review. Br J Cancer 2003; 89(5): 959-965.

      28. Lerman M, Minna JD. The international lung can­cer chromosome 3p21.3 tumor suppressor gene consor­tium. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evalua­tion of the resident candidate tumor suppressor genes. Cancer Res 2000; 60(21): 6116-6133.

      29. Witsuba I, Behrens C, Virmani AK. High resolu­tion chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60(7): 1949-1960.

      30. Minna J, Lerman M, Zabrovosky E. Chromosome 3 abnormalities in lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Rurrisi AT, Minna JD, Carbone DP, Eds. The Textbook of Lung Cancer Principles and Practice, 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2005; 129-143.

      31. Virmani AK, Zochbauer-Muller S, Rathi A. Pro­moter methylation and silencing of the retinoic acid  gene in lung carcinomas. J Natl Cancer Inst 2000; 92(16): 1303-1307.

      32. Lio C, Ling G. The expression frequency of com­mon fragile sites and genetic susceptibility to lung cancer. Cancer Genet Cytogenet 1989; 42(1): 107-114.

      33. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in non-small-cell lung cancer: Br J Cancer 2000; 82(6): 1191-1197.

      34. Skaug V, Ryberg D, Kure E, Arab M, Stangeland L, Myking A, Haugen A. p53 Mutations in defined struc­ture and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Can­cer Res 2000; 6(3): 1031-1037.

      35. Rusch VW, Klimstra DS, Ennapadama SV. Molec­ular markers help characterize neuroendocrine lung tu­mors. Ann Thorac Surg 1996; 62(3): 798-810.

      36. Rusch VW, Klimstra DS, Linkov I, Dmitrovsky E. Aberrant expression of p53 or epidermal growth factor receptor is frequent in early bronchial neoplasia and co­expression precedes SqCC. Cancer Res 1995; 55(6): 1365-1372.

      37. Kalomenidis I, Orphanidou D, Papamichalis G, Vassilakopoulos T, Skorilas A, Rasidakis A, Papastamatiou H, Jordanoglou J, Charis R. Combined expression of p53, bcl-2 and p21 proteins in lung cancer and premalignant lesions. Association with clinical charac­teristics. Lung 2001; 179(5): 265-278.

      38. Denissenko MF, Pao A, Pfeifer GP, Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 1998; 16(10): 1241-1249.

      39. Mitsudomi T, Hamajima N, Ogawa M. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6(10): 4055-4063.

      40. Leversha MA, Fielding P, Watson S, Gosney JR, Field JK. Expression of Rb, p53 and p16 in lung tumors: a validation study on tissue microarrays. J Pathol 2003; 200(5): 610-619.

      41. Beasley M, Lantuejol S, Abbondanzo S, Chu W, Hasleton P, Path F, Travis W, Brambilla E. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003; 34(2): 136-142.

      42. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188(4): 351-360.

      43. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J. Rb and p16 expression in resected non-small cell lung tumors. Cancer Res 1996; 56(15): 3415-3420.

      44. Kim D, Nelson H, Wiencke J, Zheng S, Christiani D, Wai J, Mark E, Kelsey K. p16 and histology specific methylation of CpG Islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61(8): 3419-3424.

      45. Girard L, Zochbauer-Muller S, Virmani A, Gazdar A, Minna J. Genome wide allelotyping of lung cancer identifies new regions of allelic loss, differences between SCLC and NSCLC and loci clustering. Cancer Res 2000; 60(17): 4896-4906.

      46. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF. Allele-specific chro­mosome 3p deletions occur at an early stage in the patho­genesis of lung carcinoma. JAMA 1995; 273(24): 1908.

      47. Sundaresen V, Heppell-Parton A, Coleman N, Miozzo M, Sozzi G, Ball R, Cary N, Hasleton P, Fowler W, Rabbitts P. Somatic genetic changes in lung cancer and precancerous lesions. Ann Oncol 1995; 6(Suppl 1): 27-31.

      48. Marsita CJ, Wiencke JK, Nelson HH, Kim DH, Hinds PW, Aldape K, Kelsey KT. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, p53, and survival. Cancer Genet Cytogenet 2005; 162(2): 115-121.

      49. de Lange T. Protection of mammalian telomeres. Oncogene 2002; 21(4): 532-540.

      50. Harley B. Telomere loss: mitotic clock or genetic time bomb? Mut Res 1991; 256(2-6): 271-282.

      51. Bodnar AG, Quelette M, Froklis M. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998; 279(5349): 349-352.

      52. Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF. Telomerase expression in respira­tory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997; 57(12): 2373-2377.

      53. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar A, Piatyszek MA, Shay JW. Telomerase activity in small cell and non-small cell lung cancers. J Natl Cancer Inst 1995; 87(12): 895-902.

      54. Soria JC, Xu X, Liu DD, Lee JJ, Kurie J, Morice RC, Khuri F, Mao L, Hong WK, Lotan R. Retinoic acid receptor  and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 2003; 95(2): 165-168.

      55. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1): 6-12.

      56. Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silenc­ing. Carcinogenesis 2002; 23(7): 1103-1109.

      57. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 2002; 3(6): 415-428.

      58. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermehtylation profile of human cancer. Cancer Res 2001; 61(8): 3225-3229.

      59. Toyooka S, Toyooka KO, Maruyama R, Virmani A, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna J, Gazdar A. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1(1): 61-67.

      60. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, Joste N, Baylin SB, Belinsky SA. Aberrant promoter methylation of transcription factor gene PAX5 alpha and beta in human cancers. Cancer Res 2003; 63(15): 4620-4625.

      61. Issa JP. Methylation and prognosis. Of molecular clocks and and hypermethylator phenotypes. Clin Cancer Res 2003; 9(8): 2879-2881.

      62. Toyooka S, Maruyama R, Toyooka KO. Smoke exposure, histologic type and geography-related differ­ences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003; 103(2): 153-160.

      63. Belinsky SA, Snow SS, Nikula KJ, Finch GL, Tellez CL, Palmisano WA. Aberrant CpG island methyla­tion of the p16 and estrogen receptor genes in lung tumors induced by particulate carcinogenes. Carcinogenesis 2002; 23(2): 335-339.

      64. Belinsky SA, Nikula KJ, Palmisano WA, Michel R, Saccamano G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95(20): 11891-11896.

      65. Lamy A, Sesboue R, Bourgignon J, Datur B, Metayer J, Frebourg T, Thiberville L. Aberrant methyla­tion of the CDKN2a/p16INK4a promoter region in prein­vasive bronchial lesions; a prospective study in high risk patients with invasive cancer. Int J Cancer; 2002; 100(2): 189-193.

      66. Gilliland FD, Harms HJ, Crowel RE, Li YF, Willink R, Belinsky SA. Glutathione-S-transferase P1 and NADPH quione oxidoreductase polymorphisms are associ­ated with aberrant promoter methylation of P16ink4a and O-methylguanine-DNA methyltransferase in sputum. Can­cer Res 2002; 62(8): 2248-2252.

      67. Wiencke JK. DNA adduct burden and tobacco carcinogenesis. Oncogene 2002; 21(48): 7376-7391.

      68.Cheng YW, Chen CY, Lin P. DNA adduct level in lung tissue may act as a risk biomarker of lung cancer. Eur J Cancer 2000; 36(11): 1381-1388.

      69. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 1988; 336(6201): 790-792.


Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Accepted articles
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998



 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006